Heron Therapeutics (NASDAQ:HRTX) had its price target increased by Needham & Company LLC to $42.00 in a research note released on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

HRTX has been the subject of a number of other reports. Mizuho reaffirmed a buy rating and issued a $28.00 price target on shares of Heron Therapeutics in a research note on Tuesday, January 16th. ValuEngine raised Heron Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. Leerink Swann initiated coverage on Heron Therapeutics in a research note on Tuesday, January 2nd. They issued an outperform rating and a $22.00 price target for the company. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the company a buy rating in a research note on Monday, January 15th. Finally, Cowen reissued a buy rating and set a $40.00 target price on shares of Heron Therapeutics in a research note on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of Buy and a consensus price target of $33.00.

How to Become a New Pot Stock Millionaire

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at $27.15 on Tuesday. Heron Therapeutics has a 52 week low of $12.70 and a 52 week high of $32.70.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.29). The company had revenue of $10.05 million during the quarter, compared to the consensus estimate of $9.00 million. Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. analysts expect that Heron Therapeutics will post -2.53 EPS for the current fiscal year.

In related news, VP Kimberly Manhard sold 18,000 shares of the stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $30.00, for a total transaction of $540,000.00. Following the completion of the sale, the vice president now directly owns 18,000 shares of the company’s stock, valued at approximately $540,000. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Barry D. Quart sold 100,000 shares of the stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $29.75, for a total value of $2,975,000.00. Following the sale, the chief executive officer now directly owns 167,993 shares of the company’s stock, valued at $4,997,791.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 225,584 shares of company stock valued at $6,141,680. 19.93% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of HRTX. Parametric Portfolio Associates LLC boosted its position in Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after acquiring an additional 771 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Heron Therapeutics by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock worth $482,000 after acquiring an additional 8,135 shares during the last quarter. Chartwell Investment Partners LLC acquired a new position in Heron Therapeutics during the 3rd quarter worth approximately $2,340,000. Trexquant Investment LP acquired a new position in Heron Therapeutics during the 3rd quarter worth approximately $206,000. Finally, Wells Fargo & Company MN boosted its position in Heron Therapeutics by 202.1% during the 3rd quarter. Wells Fargo & Company MN now owns 130,374 shares of the biotechnology company’s stock worth $2,106,000 after acquiring an additional 87,212 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Needham & Company LLC Boosts Heron Therapeutics (HRTX) Price Target to $42.00” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/needham-company-llc-boosts-heron-therapeutics-hrtx-price-target-to-42-00/1959893.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.